Previous Page  23 / 29 Next Page
Information
Show Menu
Previous Page 23 / 29 Next Page
Page Background

La IMTP como QT paliativa en segunda línea de CECCR/M:

Estudio CHECKMATE -141 con NIVOLUMAB

Nivolumab

(n = 240)

Investigator’s Choice

(n = 121)

Objective response rate, n (%)

32 (13.3)

7 (5.8)

95% CI

9.3, 18.3

2.4, 11.6

Best overall response, n (%)

Complete response

6 (2.5)

1 (0.8)

Partial response

26 (10.8)

6 (5.0)

Stable disease

55 (22.9)

43 (35.5)

Progressive disease

100 (41.7)

42 (34.7)

Not determined

53 (22.1)

29 (24.0)

Time to response, mo

Median (range)

2.1 (1.8–7.4)

2.0 (1.9–4.6)